Moderna Returns to Profit and Raises Guidance — Then Bets the Company on Personalized Cancer Vaccines

Moderna's Q3 2026 marks a financial inflection: $200M net income, 29% revenue growth, and a raised full-year outlook. The real story is the pivot from COVID vaccines to individualized cancer therapy, where a Phase 3 melanoma trial cut recurrence risk by 42%.

Moderna posted $200 million in net income for Q3 2026, returning to profitability after a period of post-pandemic revenue contraction. Revenue grew 29% year-over-year, driven by uptake of mRNASPIKE in the US and strategic partnerships in the UK and Canada. The company raised its full-year revenue growth guidance from "up to 10%" to a 15–25% range, citing strong demand visibility into Q4.

The financial turnaround rests on two legs: cost discipline and pipeline diversification. Operating cash costs fell 10% year-over-year, and R&D spending was trimmed by $200 million through the scaling back of infectious disease trials. The company now has five approved infectious disease products, including the first mRNA-based influenza vaccine to reach market. But management's attention — and capital — is pointed squarely at oncology. The headline clinical result is Intismeran, a personalized cancer treatment that reduced recurrence or death risk by 42% in a Phase 3 adjuvant melanoma trial, outperforming Keytruda alone. Management calls this the first individualized cancer therapy to demonstrate statistically significant clinical benefit over a standard of care in a pivotal setting. The mechanism works by training mRNA to trigger T-cell responses against neoantigens — tumor-specific mutations unique to each patient. Management describes the neoantigen-selection algorithm as a "gold mine" that improves with every patient treated, creating what they argue is a durable competitive moat. Moderna plans to file a Biologics License Application for Intismeran by end of 2026, targeting FDA approval in 2027. The pricing strategy remains undefined — management says only that it will collaborate with Merck to set a price reflecting "the value delivered to the healthcare system." This vague framing is worth watching: personalized therapies are expensive to manufacture by definition, and the payer conversation will be contentious. Capital allocation reflects the oncology bet. The company raised $3 billion through zero-interest convertible bonds, explicitly earmarked for cancer pipeline growth. It also absorbed a $950 million litigation settlement during the quarter, which management flagged as the primary drag on working capital. Meanwhile, the norovirus vaccine program (mRNA-1403) failed to meet early success criteria at interim analysis, and enrollment was paused pending regulatory consultation. The MMA pivotal trial is on hold until propionic acidemia results arrive. The strategic picture is clear: Moderna is using COVID-era cash flow and balance sheet engineering to fund a transformation from a single-product vaccine company into a platform oncology player. COO Juan Andres has returned to the executive committee to oversee manufacturing scale-up for personalized therapies — a signal that the company sees production logistics as the binding constraint, not science. Upcoming catalysts include a Phase 2 renal cell carcinoma readout in late 2026 or early 2027, and a PA registration trial. The risk is concentration. Moderna's oncology thesis depends on Intismeran's regulatory success, Merck's cooperation on pricing, and the assumption that the neoantigen algorithm's data advantage compounds faster than competitors can replicate it. If the BLA hits delays or payer pushback is severe, the $3 billion in convertible debt becomes a liability rather than a springboard. The company is making a single, large, directional bet — and the market will grade the homework in 2027.